Project Grant R35GM166022
- The National Institute of General Medical Sciences awarded $433,125 to the University of California, Los Angeles on August 10, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, Assistance Listing). Andrew Holbrook, a biostatistician at UCLA, will develop AI-accelerated inference strategies and open-source software for Bayesian hierarchical models applied to high-impact biostatistical problems. The work addresses a computational bottleneck in biomedical research:...
- The National Institute of General Medical Sciences awarded The Regents of the University of California, San Francisco $445,049 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop membrane-inspired lipid nanoparticles for cell-type-specific expression of programmable RNA. The recipient will design novel lipid nanoparticle formulations to achieve precise, scalable delivery of biomolecules to specific cell types, combining bio-inspired...
- The National Science Foundation Division of Molecular and Cellular Biosciences awarded the University of California, San Diego $800,000 on June 15, 2026, under the Biological Sciences program (CFDA 47.074) to systematically identify, functionally characterize, and solve high-resolution structures of RNA tertiary motifs in human cells. The research addresses a significant gap in understanding human gene regulation by using innovative chemical probing technology to discover and visualize...
- The National Institute of General Medical Sciences awarded the University of California, Los Angeles $286,729 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research defining the dynamics of eukaryotic translation and messenger RNA decay. The research uses in vitro-reconstituted systems, biochemical techniques, single-molecule fluorescence spectroscopy, and structural approaches to determine how translation concludes on normal and...
- The National Institute of General Medical Sciences, a bureau of the National Institutes of Health within the Department of Health and Human Services, awarded $301,936 to the University of California, Los Angeles on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The award funds data-science-guided study and design of phosphoranyl radical-mediated reactions for the discovery of novel pharmaceutical compounds. The research builds a comprehensive,...
- The National Institute of General Medical Sciences awarded the University of California, Los Angeles $433,125 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop imaging-based molecular recording methods that reconstruct the signaling history of individual cells during development. The funded research extends a signal-recording approach that uses regulated CRISPR base editors to generate mutations in engineered genomic target sites at rates...
- The National Institute of General Medical Sciences awarded the University of California, Los Angeles $420,981 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop engineered enzymatic catalysts for asymmetric hydrogen atom transfer reactions in synthetic chemistry. The research integrates organic chemistry, protein engineering, bioinorganic chemistry, and computational modeling to design and evolve biocatalysts that enable...
- The National Institute of General Medical Sciences awarded the University of California, Los Angeles $406,432 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop and apply mass spectrometry-based chemoproteomic technologies that identify functional and redox-sensitive cysteine residues in proteins, with the goal of discovering therapeutically relevant cysteines to support covalent drug development. The research program focuses on three main...
- The National Institute of General Medical Sciences awarded The University Corporation $405,625 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to discover and characterize thermoregulatory RNA elements in bacteria, phages, chloroplasts, and mitochondria. The funded work expands discovery and characterization of thermoregulatory RNAs—structured RNA elements that respond to heat stress—across prokaryotic and organellar genomes over five years. A major...
- The National Institute of General Medical Sciences awarded Northwestern University a Project Grant for $382,751 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to study dynamic RNA folding and function. The research addresses how nascent RNA structures influence gene expression during transcription, translation, splicing, and polyadenylation. The work focuses on riboswitches—non-coding regulatory RNAs that bind ligands and control gene expression...
The National Institute of General Medical Sciences awarded $344,359 to the University of California, Los Angeles on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on programmable RNA materials for structure, function, and applications. The research, led by Principal Investigator Jaimie Marie Stewart in UCLA's Department of Bioengineering, establishes design rules and platform technologies for programmable RNA materials that are robust, stimuli-responsive, and capable of tuning immune response. The work integrates chemical modification with quantitative biophysical and cellular measurements to define how sequence, structure, and chemistry govern RNA assembly, stability, and biological recognition. Specific deliverables include engineered RNA domains that translate nanoscale interactions into measurable macroscopic outputs for molecular sensing, and functionalized RNA assemblies incorporating decoys and aptamers to modulate NF-kB innate immune pathways. The anticipated outcome is a comprehensive framework of validated principles, design strategies, and protocols for constructing RNA assemblies that detect disease-associated biomarkers and deliver therapeutic RNAs, expanding the RNA therapeutic toolbox beyond traditional RNA approaches. Performance occurs at UCLA's Los Angeles, California campus. The award period runs from September 1, 2026, through August 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $344.4k | 8/21/26 |